VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study ; volume:14 ; number:1 ; day:9 ; month:4 ; year:2024 ; pages:1-4 ; date:12.2024
Blood cancer journal ; 14, Heft 1 (9.4.2024), 1-4, 12.2024
- Urheber
-
Nørgaard, Jakob Nordberg
Moore, Kari Lenita Falck
Slørdahl, Tobias S.
Vik, Anders
Tvedt, Tor Henrik Anderson
Schjesvold, Fredrik
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-024-01047-1
- URN
-
urn:nbn:de:101:1-2406241147031.741285930965
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nørgaard, Jakob Nordberg
- Moore, Kari Lenita Falck
- Slørdahl, Tobias S.
- Vik, Anders
- Tvedt, Tor Henrik Anderson
- Schjesvold, Fredrik
- SpringerLink (Online service)
Ähnliche Objekte (12)
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
WA DDR/VRD
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
Parteiarbeit der Parteiorganisation VRD
Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
Current status of autologous stem cell transplantation for multiple myeloma
Multiple Myeloma: Front Line Therapy and Autologous Stem Cell Transplantation
Labor induction in China: a nationwide survey
Gesundheitsunterlagen eines Unteroffiziers des VRD
Gesundheitsunterlagen eines Unteroffiziers der VRD
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
WA DDR/VRD
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
Parteiarbeit der Parteiorganisation VRD
Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
Current status of autologous stem cell transplantation for multiple myeloma
Multiple Myeloma: Front Line Therapy and Autologous Stem Cell Transplantation
Labor induction in China: a nationwide survey
Gesundheitsunterlagen eines Unteroffiziers des VRD
Gesundheitsunterlagen eines Unteroffiziers der VRD
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
WA DDR/VRD
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
Parteiarbeit der Parteiorganisation VRD
Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
Current status of autologous stem cell transplantation for multiple myeloma
Multiple Myeloma: Front Line Therapy and Autologous Stem Cell Transplantation
Labor induction in China: a nationwide survey
Gesundheitsunterlagen eines Unteroffiziers des VRD